There were no significant differences between the TNFi groups in terms of sex, age, HLA-B27 positivity, history of AU before TNFi initiation, other extra-articular manifestations (i.e., psoriasis and inflammatory bowel disease), or number of recurrences prior to TNFα inhibitor use (Table 2), indicating baseline comparability. The gene discussed is TNF; the disease is psoriasis.